Download Files:
Products Details
Product Description
– Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis[1].
Web ID
– HY-145829
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C36H39ClN10O7
References
– [1]Zhao J, et al. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem. 2022;65(6):4926-4948.
Molecular Weight
– 759.21
SMILES
– O=C(O)C1=CC(/N=N/C2=CC=C(COC(NCCCN(C)C(N3C=CC4=C(NC[C@@H]5CN(C(CC#N)=O)CC[C@H]5C)N=CN=C43)=O)=O)C(Cl)=C2)=CC=C1O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Apoptosis;JAK
Pathway
– Apoptosis;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
